Skip to Main Content

WASHINGTON — Less than six months ago, President Trump stood at a podium and roiled the pharmaceutical industry with an emphatic declaration that its executives are “getting away with murder.”

If Congress has its way, the same president will soon sign into law a massive package that is at the top of the industry’s wish list: a reauthorization of drug makers’ funding agreements with the Food and Drug Administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • My son is a PHD on porting. He is an expat oOn biotechnology & have a post graduate deploma in bio informatics and working 11 years as professor. He desires to work with a good package.

Comments are closed.